Last reviewed · How we verify

Capecitabine(Aibin)

The First Affiliated Hospital of Henan University of Science and Technology · Phase 3 active Small molecule

Capecitabine(Aibin) is a Fluoropyrimidine antimetabolite Small molecule drug developed by The First Affiliated Hospital of Henan University of Science and Technology. It is currently in Phase 3 development for Metastatic colorectal cancer, Metastatic breast cancer, Gastric cancer. Also known as: Aibin.

Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth.

Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth. Used for Metastatic colorectal cancer, Metastatic breast cancer, Gastric cancer.

At a glance

Generic nameCapecitabine(Aibin)
Also known asAibin
SponsorThe First Affiliated Hospital of Henan University of Science and Technology
Drug classFluoropyrimidine antimetabolite
TargetThymidylate synthase
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Capecitabine is an oral fluoropyrimidine carbamate that undergoes hepatic and tissue-level enzymatic conversion to 5-fluorouracil (5-FU). The active 5-FU metabolite inhibits thymidylate synthase, blocking dTMP synthesis and DNA replication, while also incorporating into RNA to disrupt protein synthesis. This mechanism preferentially affects rapidly dividing cancer cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Capecitabine(Aibin)

What is Capecitabine(Aibin)?

Capecitabine(Aibin) is a Fluoropyrimidine antimetabolite drug developed by The First Affiliated Hospital of Henan University of Science and Technology, indicated for Metastatic colorectal cancer, Metastatic breast cancer, Gastric cancer.

How does Capecitabine(Aibin) work?

Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth.

What is Capecitabine(Aibin) used for?

Capecitabine(Aibin) is indicated for Metastatic colorectal cancer, Metastatic breast cancer, Gastric cancer, Pancreatic cancer.

Who makes Capecitabine(Aibin)?

Capecitabine(Aibin) is developed by The First Affiliated Hospital of Henan University of Science and Technology (see full The First Affiliated Hospital of Henan University of Science and Technology pipeline at /company/the-first-affiliated-hospital-of-henan-university-of-science-and-technology).

Is Capecitabine(Aibin) also known as anything else?

Capecitabine(Aibin) is also known as Aibin.

What drug class is Capecitabine(Aibin) in?

Capecitabine(Aibin) belongs to the Fluoropyrimidine antimetabolite class. See all Fluoropyrimidine antimetabolite drugs at /class/fluoropyrimidine-antimetabolite.

What development phase is Capecitabine(Aibin) in?

Capecitabine(Aibin) is in Phase 3.

What are the side effects of Capecitabine(Aibin)?

Common side effects of Capecitabine(Aibin) include Hand-foot skin reaction, Diarrhea, Nausea, Vomiting, Stomatitis, Fatigue.

What does Capecitabine(Aibin) target?

Capecitabine(Aibin) targets Thymidylate synthase and is a Fluoropyrimidine antimetabolite.

Related